Spots Global Cancer Trial Database for darbepoetin alfa
Every month we try and update this database with for darbepoetin alfa cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study | NCT00115167 | Anemia Cancer | Placebo Darbepoetin alf... | 18 Years - | Amgen | |
| Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer | NCT00381836 | Prostatic Neopl... Anemia | Darbepoetin Alf... | 18 Years - | University of Aarhus | |
| Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies | NCT00239239 | Non-Myeloid Mal... Anemia Cancer | Darbepoetin alf... | 18 Years - | Amgen | |
| A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa | NCT00119613 | Small Cell Lung... | placebo darbepoetin alf... | 18 Years - | Amgen | |
| Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer | NCT00146562 | Breast Cancer Stage I Breast ... Stage II Breast... | Darbepoetin Alf... Pegfilgrastim Paclitaxel Doxorubicin Cyclophosphamid... | 18 Years - | Dana-Farber Cancer Institute | |
| Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | NCT01362140 | MDS | Darbepoetin alf... Placebo | 18 Years - | Amgen | |
| Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy | NCT00120679 | Non-Small Cell ... Anemia | darbepoetin alf... recombinant hum... | 18 Years - | Amgen | |
| Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer | NCT00309920 | Breast Cancer | darbepoetin alf... cyclophosphamid... docetaxel doxorubicin hyd... epirubicin hydr... fluorouracil | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma | NCT00058422 | Lymphoma | darbepoetin alf... filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... indium In 111 i... yttrium Y 90 ib... | 60 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA | NCT04798339 | Myelodysplastic... | Canakinumab Inj... Darbepoetin Alf... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | NCT00858364 | Non-Small Cell ... Anemia Cancer Lung Cancer | Darbepoetin alf... Placebo | 18 Years - | Amgen | |
| Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy | NCT00111137 | Cancer Non-Myeloid Mal... | rHuEPO Darbepoetin alf... | 18 Years - | Amgen | |
| The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery | NCT00122720 | Colorectal Canc... | Darbepoetin Alf... | 18 Years - | Herning Hospital | |
| Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer | NCT00091858 | Anemia Cancer | Darbepoetin Alf... Placebo | 18 Years - | Amgen | |
| Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma | NCT00058422 | Lymphoma | darbepoetin alf... filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... indium In 111 i... yttrium Y 90 ib... | 60 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor | NCT00359840 | Anemia | darbepoetin alf... | 20 Years - 74 Years | Kyowa Kirin Co., Ltd. | |
| Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer | NCT00309920 | Breast Cancer | darbepoetin alf... cyclophosphamid... docetaxel doxorubicin hyd... epirubicin hydr... fluorouracil | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Darbepoetin Alfa With or Without Intravenous (IV) Iron | NCT00401544 | Anemia Non-Myeloid Mal... | darbepoetin alf... IV iron dextran | 18 Years - | Amgen | |
| A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy. | NCT00327535 | Anemia | Darbepoetin alf... methoxy polyeth... methoxy polyeth... methoxy polyeth... | 18 Years - | Hoffmann-La Roche | |
| Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer | NCT00381836 | Prostatic Neopl... Anemia | Darbepoetin Alf... | 18 Years - | University of Aarhus | |
| A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) | NCT00230321 | Blood Cancer Myelodysplastic... Myelodysplastic... | Darbepoetin alf... | 18 Years - | Stanford University | |
| Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00077311 | Anemia Drug/Agent Toxi... Lung Cancer Neutropenia | darbepoetin alf... pegfilgrastim cisplatin docetaxel BNP7787 | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA | NCT04798339 | Myelodysplastic... | Canakinumab Inj... Darbepoetin Alf... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | NCT01362140 | MDS | Darbepoetin alf... Placebo | 18 Years - | Amgen | |
| Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies | NCT00036023 | Lymphoma Breast Neoplasm... Lung Neoplasms Multiple Myelom... Chronic Lymphoc... | darbepoetin alf... | 18 Years - | Amgen | |
| A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp® | NCT00117117 | Anemia | Aranesp | 18 Years - | Amgen | |
| AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies | NCT00135317 | Cancer | darbepoetin alf... | 18 Years - | Amgen | |
| Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma | NCT00058422 | Lymphoma | darbepoetin alf... filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... indium In 111 i... yttrium Y 90 ib... | 60 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy | NCT00120705 | Neoplasms Anemia | darbepoetin alf... | 18 Years - | Amgen | |
| Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies | NCT00239239 | Non-Myeloid Mal... Anemia Cancer | Darbepoetin alf... | 18 Years - | Amgen | |
| Darbepoetin Alfa With or Without Intravenous (IV) Iron | NCT00401544 | Anemia Non-Myeloid Mal... | darbepoetin alf... IV iron dextran | 18 Years - | Amgen | |
| Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy | NCT00121030 | Gynecological M... Genital Neoplas... Anemia | darbepoetin alf... recombinant hum... | 18 Years - | Amgen | |
| A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor | NCT00359840 | Anemia | darbepoetin alf... | 20 Years - 74 Years | Kyowa Kirin Co., Ltd. | |
| Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy | NCT00111462 | Anemia Non-Myeloid Mal... Cancer | Darbepoetin alf... | - | Amgen | |
| A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy. | NCT00327535 | Anemia | Darbepoetin alf... methoxy polyeth... methoxy polyeth... methoxy polyeth... | 18 Years - | Hoffmann-La Roche | |
| A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy | NCT00117624 | Anemia | darbepoetin alf... | 18 Years - | Amgen | |
| Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies | NCT00239239 | Non-Myeloid Mal... Anemia Cancer | Darbepoetin alf... | 18 Years - | Amgen | |
| Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia | NCT00264108 | Anemia Neoplasms | Darbepoetin alf... Epoetin alfa | 18 Years - | Janssen-Cilag B.V. | |
| Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation | NCT00355407 | Hematologic Mal... | Darbepoetin alf... | 18 Years - | Dana-Farber Cancer Institute | |
| Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide | NCT00283621 | Sarcoma | Aranesp (darbep... Neulasta (pegfi... Adriamycin Ifosfamide | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Dosing and Outcomes Study of Erythropoietic Stimulating Therapies in Patients With Chemotherapy Induced Anemia | NCT00212862 | Anemia Cancer | Patients with c... | 18 Years - | Ortho Biotech Products, L.P. | |
| Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer | NCT00095277 | Anemia | Darbepoetin Alf... | 18 Years - | Amgen | |
| Treatment for Patients Suffering From Anemia Due to Chemotherapy | NCT00120692 | Breast Cancer Anemia | Darbepoetin Alf... Recombinant Hum... | 18 Years - | Amgen | |
| Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia | NCT00264108 | Anemia Neoplasms | Darbepoetin alf... Epoetin alfa | 18 Years - | Janssen-Cilag B.V. | |
| Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS | NCT00520468 | Myelodysplastic... | Erythropoietin Cyclosporin A G-CSF Prednisone | - | M.D. Anderson Cancer Center | |
| Darbepoetin Alfa MDS Companion Protocol | NCT02175277 | Myelodysplastic... | Darbepoetin Alf... | 18 Years - | Amgen | |
| A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients | NCT00344409 | Anemia | darbepoetin alf... | 20 Years - 74 Years | Kyowa Kirin Co., Ltd. | |
| Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia | NCT00315484 | Anemia Chemotherapy | Epoetin alfa an... | 18 Years - | Ortho Biotech Products, L.P. | |
| Darbepoetin Alfa and Anemia of Cancer | NCT00989092 | Anemia Anemia of Cance... Cancer Carcinoma Neoplasms Non-Myeloid Mal... | darbepoetin alf... | 18 Years - | Amgen | |
| A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy | NCT00386152 | Neoplasms Anemia Cancer | epoetin alfa darbepoetin alf... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy | NCT00120705 | Neoplasms Anemia | darbepoetin alf... | 18 Years - | Amgen | |
| Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA | NCT04798339 | Myelodysplastic... | Canakinumab Inj... Darbepoetin Alf... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer | NCT00091858 | Anemia Cancer | Darbepoetin Alf... Placebo | 18 Years - | Amgen | |
| Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | NCT00858364 | Non-Small Cell ... Anemia Cancer Lung Cancer | Darbepoetin alf... Placebo | 18 Years - | Amgen | |
| Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia | NCT00264108 | Anemia Neoplasms | Darbepoetin alf... Epoetin alfa | 18 Years - | Janssen-Cilag B.V. | |
| Treatment for Patients Suffering From Anemia Due to Chemotherapy | NCT00120692 | Breast Cancer Anemia | Darbepoetin Alf... Recombinant Hum... | 18 Years - | Amgen | |
| A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa | NCT00119613 | Small Cell Lung... | placebo darbepoetin alf... | 18 Years - | Amgen | |
| Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | NCT01362140 | MDS | Darbepoetin alf... Placebo | 18 Years - | Amgen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
